Avalo Therapeutics (AVTX) Shares Outstanding (Diluted Average) (2015 - 2026)

Avalo Therapeutics has reported Shares Outstanding (Diluted Average) for 7 years, with the latest figure at $20.1 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Diluted Average) rose 91.22% year-over-year to $20.1 million; the trailing twelve-month figure through Mar 2026 stood at $20.1 million (up 91.22% YoY), and the FY2025 full-year result was $13.4 million, up 78.82% from the prior year.
• Shares Outstanding (Diluted Average) for Q1 2026 stood at $20.1 million, up from $13.4 million in the prior quarter.
• The five-year high for Shares Outstanding (Diluted Average) was $20.1 million in Q1 2026, with the low at $859381.0 in Q1 2024.
• Historically, Shares Outstanding (Diluted Average) has averaged $10.1 million across 3 years, with a median of $10.5 million in 2025.
• The largest YoY upside for Shares Outstanding (Diluted Average) was 1123.54% in 2025 against a maximum downside of 39.46% in 2025.
• Avalo Therapeutics' Shares Outstanding (Diluted Average) stood at $7.5 million in 2024, then jumped by 78.82% to $13.4 million in 2025, then soared by 50.0% to $20.1 million in 2026.
• The last three Shares Outstanding (Diluted Average) figures came in at $20.1 million (Q1 2026), $13.4 million (Q4 2025), and $14.0 million (Q3 2025), per Business Quant data.